Direct comparison
Royalty vs. Equity Licensing Compensation
How universities choose royalty, equity, or hybrid compensation when licensing patents to startups, and why cash-poor licensees change the calculus.
Side-by-side comparison
| Dimension | Running Royalty | Equity Stake | Hybrid Structure |
|---|---|---|---|
| What it is | A recurring percentage of the licensee's net product sales, paid for as long as the license and patent remain in force | Shares, units, or warrants in the licensee company, taken in place of or alongside cash consideration | A reduced running royalty combined with a smaller equity stake, often with milestone payments layered in |
| Requires licensee revenue | Yes -- generates nothing until the licensee has sales | No -- generates nothing until an exit, but doesn't depend on sales existing yet | Partially -- the royalty component still depends on sales, but the license isn't solely dependent on them |
| Typical licensee profile | Established company with existing or near-term product revenue | Early-stage, cash-poor startup unable to pay meaningful upfront fees or royalties | Startup with some near-term revenue prospect but still limited cash |
| When value is realized | Incrementally, as sales occur | Only on a liquidity event -- acquisition, IPO, or share sale; worthless if the company never exits | Both -- incremental royalty income plus potential exit value |
| Administrative burden | Moderate -- sales reports, audit rights, minimum royalty tracking | Higher -- cap-table monitoring, dilution tracking, conflict-of-interest oversight, eventual share disposition | Highest -- combines royalty administration with equity monitoring |
| Institutional risk profile | Lower -- tied directly to actual sales, no dependence on an exit event | Higher -- concentrated bet on one company's eventual success, subject to dilution | Balanced -- some cash exposure to sales, some upside exposure to an exit |
| Conflict-of-interest exposure | Standard license-level COI management | Elevated, especially if a faculty inventor is also a founder or officer of the licensee | Elevated, same as equity component |
| Common companion terms | Upfront fee, minimum annual royalties, patent cost reimbursement | Anti-dilution protection (or its deliberate absence), board observer/information rights | Milestone payments, reduced upfront fee, staged diligence obligations |
Common questions
FAQ
Why would a university take equity instead of a royalty?+
Because an early-stage, cash-poor startup often cannot pay a meaningful upfront fee or running royalty at all. Equity lets the institution capture value from the license in a form the startup can actually afford to give -- ownership -- rather than cash it doesn't have. The trade-off is that equity is only worth something if the company eventually has a liquidity event.
Is equity riskier for a university than a royalty?+
Generally yes, in the sense that equity depends entirely on the licensee eventually being acquired, going public, or creating some other exit; a company that never exits leaves the equity stake worth nothing. A running royalty, by contrast, generates at least some cash the moment the licensee has any sales, however modest.
What is a hybrid royalty-equity licensing structure?+
A license that combines a reduced running royalty with a smaller equity stake, and often milestone payments, rather than relying on one mechanism alone. It lets an institution's compensation track a startup's actual ability to pay cash at each stage of development while retaining some exposure to a future exit.
Does the university keep its equity stake forever?+
Not necessarily -- institutional policy typically governs when and how the institution can sell shares it receives through a license, and whether the stake carries anti-dilution protection through subsequent financing rounds. This is usually addressed in the institution's own equity-holding and conflict-of-interest policies, not in the license agreement's core royalty terms.
